Blog

A Call for System Readiness at the FDA Hearing on Sept. 14

As the future of psychedelic therapies approaches an inflection point, mental health leaders call for action on system readiness National mental health leaders are pushing for evidence-based strategies that support patient safety and access. The hearing precedes an Oct. 5 deadline for comments on the future of psychedelic drugs WASHINGTON, DC — The Food ...

A Collaborative Path Toward Care: Our Shared Comments to HRSA

Four of the country's mental health organizations came together last month to shape a response toward helping to define how psychedelic-assisted therapy reaches patients: who is prepared to deliver it safely, and how do we get them ready? BrainFutures, Mental Health America, National Council for Mental Wellbeing, and Meadows Mental Health Policy Institute join...

The Brain Skills Behind the Behavior: What Every Parent Needs To Know

How many times have you asked yourself, “Why is my child acting like this?” Perhaps you asked them to do what seemed like a simple task. Then, led to a meltdown, or they forgot to do it, or they didn't know where to start. Most of the behaviors that frustrate parents happen because children are still developing their executive functions, such as working...

Psilocybin and CBT for Cocaine Use Disorder: A Conversation with Sara Lappan, PhD

Interview with Jazz Glastra and Sarah Lappan, PhD Cocaine use disorder is a serious behavioral health condition, with mortality rates for this population estimated to be 4 to 8 times greater than the general population (source). To date, there are no FDA-approved drugs that have shown efficacy for treating this condition. Dr. Sara Lappan, PhD is one of ...

BrainFutures' Statement on the Executive Order Accelerating Psychedelic Research and Access

April 18, 2026 Baltimore, MD — Today BrainFutures welcomed President Trump's executive order, “Accelerating Medical Treatment for Serious Mental Illness,” which directs federal support for psychedelic research and removes unnecessary barriers to research and compassionate use. It also calls on the FDA to use expedited approval pipelines for psychedelics ...

Psychedelic Science Update: A Smoking Cessation Interview

Interview with Jazz Glastra and Dr. Matthew Johnson An astounding 14% of all deaths worldwide are due to smoking. Dr. Matthew Johnson, Professor of Psychiatry and Behavioral Science at Johns Hopkins University, is the principal investigator on a new study that looks at the efficacy of psilocybin for smoking cessation. This is the largest psilocybin stud...

Healing Hearts and Minds: Ali Smith on the Science of Calm

Interview with Sarah Norman and Ali Smith As varied as the colors, textures, and patterns on a yoga mat can be, so are the stories of the people on those mats. From youth to seniors, Holistic Life Foundation’s Co-Founder, Ali Smith, is changing lives and communities through an evidence-based yoga and mindfulness program. More than 200,000 students a...

Reforming Outdated Barriers to Research on Mental Health and Addiction Treatment

Written by Bridget McQuillan and Jazz Glastra "As a researcher, I always hesitate to go into doing research with Schedule I drugs,” said Dr. Nora Volkow, Director of the National Institute on Drug Abuse, or NIDA, in 2021 (Jager, 2021). NIDA, part of the federal government’s National Institutes of Health, funds and conducts billions of dollars’ wort...

Event Announcement: Welcome to the Future of Rapid-Acting Mental Health Treatments

On May 18, join BrainFutures and the Frontier Psychiatrists at Rapid-Acting Mental Health Treatment (RAMHT 2025) in Los Angeles, CA, as we explore the latest developments in rapid-acting treatments for mental health. The event takes place at the Skyline Loft on the second night of the American Psychiatric Association annual conference less than a mile from the co...

Live Provider Roundtable: Integrating Psychedelic Therapies into Healthcare

Save the Date! BrainFutures is excited to invite you to a Virtual Provider Roundtable on April 1st at 12 PM EST / 9 AM PST. Click here to register now to join the conversation!  This session is a follow-up to BrainFutures and the Collaborative of the Economics for Psychedelics’ new whitepaper, Scaling Psychedelics in the Health System. This roundtable w...